Stefan Oschmann appointed chief executive of Merck KGaA
Germany's Merck KGaA has appointed Stefan Oschmann as chief executive and chairmanof the executive board.
Dr Oschmann will replace Karl-Ludwig Kley who is retiring, and has been a member of the Merck executive board since 2011. He was initially head of the pharma business before being appointed deputy chairman of the executive board and deputy chief executive officer at the beginning of 2015.
Prior to joining Merck, Dr Oschmann worked for more than 20 years at the US company Merck & Co (NYSE: MRK), and is also president of the International Federation of Pharmaceutical Manufacturers & Associations and vice president of the European Federation of Pharmaceutical Industries and Associations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze